FOI_9645

Internal Reference Number: FOI_9645

Date Request Received: 15/09/2026 00:00:00

Date Request Replied To: 28/09/2026 00:00:00

This response was sent via: By Email

Request Summary: intra-vitreal injections or implants

Request Category: Researcher


Question Number 1: I am analysing the usage of intra-vitreal injections or implants by the NHS. I would greatly appreciate if you could answer the following questions: 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2026: • Aflibercept – Eylea only (Any strength: 2mg or 8mg) • Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution) • Aflibercept - Biosimilar (any brand other than Eylea) • Bevacizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - including all Biosimilars *If Eylea cannot be split by 2mg or 8mg strength, please provide the total number of injections/implants of Eylea

Answer To Question 1: Please see response to both questions attached. To accompany this answer to question 1 please also see the documents listed below: 13977 - FOI_9645 - intra-vitreal injections or implants.xlsx

Question Number 2: Please provide the number of injections/implants by eye condition for the four-month period from May to August 2026: Please note, if a patient has received multiple injection/implants in the time period sepcificied of May to August 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two • Aflibercept – Eylea only (Any strength: 2mg or 8mg) • Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution) • Aflibercept - Biosimilar (any brand other than Eylea) • Bevacizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - including all Biosimilars *If Eylea cannot be split by 2mg or 8mg strength, please provide the total number of injections/implants of Eylea used for each indication See attached

Answer To Question 2: Please see response to both questions attached. To accompany this answer to question 2 please also see the documents listed below: FOI 9645 Q2.docx
Please see Attachments:



To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.